Dow, S&P 500 Futures Climb As House Votes To Rescind Trump Tariffs: Why VKTX, NVCR, APP, CRM, QS Are Trending After-Hours
U.S. stock futures mostly rose late Wednesday as traders reacted to a strong January jobs report and a House vote to rescind Trump's Canadian tariffs. VKTX shares jumped 9% after announcing late-stage obesity drug trials. CRM hit a 52-week low amid AI concerns. NVCR surged 30% after FDA approval for a pancreatic cancer treatment. QS rose 10% despite reporting a quarterly loss. Retail investors increased purchases of software stocks, with IGV seeing record activity. The 10-year Treasury yield ros
How this was made
The 30-second read
Why it matters
Each ticker's move reflects a distinct catalyst, ranging from FDA approval to clinical trial updates, providing short‑term trading opportunities.
Market read
The mix of biotech approvals, tech earnings, and policy developments creates a heterogeneous set of short‑term trade ideas across sectors.
What to watch
The House vote on tariffs could trigger policy volatility; retail sentiment metrics suggest low conviction despite price swings.
Background
The article aggregates after‑hours price reactions to several company‑specific news items while noting broader macro themes such as the U.S. tariff vote and job data.
Ticker impact
Shares jumped ~9% after-hours as VKTX announced plans to advance its oral obesity drug into late‑stage studies in Q3 2026.
Potential further intraday rally if investors add to positions.
First disclosure of late‑stage trial plans for a high‑interest obesity asset.
Salesforce fell to a fresh 52‑week low amid concerns over AI tools and internal pressure to drop business with ICE.
Likely continued downside unless new guidance emerges.
First report of internal employee pressure and AI‑related worries.
AppLovin shares dropped >6% after-hours despite a beat quarter and upbeat guidance, after a short‑seller retracted allegations.
Modest further decline expected; volatility may rise.
First report of the retraction and its market impact.
Novocure surged >30% in extended trading after FDA approval of Optune Pax for advanced pancreatic cancer.
Potential continued upside as market digests the approval.
First disclosure of FDA approval for a new indication.
QuantumScape shares rose >10% after reporting a Q4 loss in line with expectations and disclosing $110.5 M operating expenses.
Limited further move unless new guidance is issued.
First report of quarterly results and expense details.
Market effects
Tech‑software ETFs face pressure from retail buying trends; biotech gains from FDA approvals.
U.S. futures edged higher; Canadian tariff vote adds modest bullish bias to trade‑sensitive sectors.
Tariff reversal discussion may influence cross‑border supply chains and commodity flows.
Counterpoint
Despite strong price moves, underlying fundamentals (e.g., CRM AI concerns, APP short‑seller drama) may limit sustained upside.
Key entities
- companyViking Therapeutics
Biotech advancing obesity drug.
- companySalesforce
Enterprise software firm facing AI and internal pressure issues.
- companyAppLovin
Mobile ad tech firm with earnings beat and short‑seller controversy.
- companyNovocure
Oncology device maker receiving FDA approval.
- companyQuantumScape
Solid‑state battery developer reporting quarterly results.
